Parabilis Medicines, Inc. Common Stock PBLS
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $41.25 (+55.6% upside)
Key Stats
- Today's Range
- $24.75 – $27.36
- 50-Day Range
- $22.66 – $42.48
- 52-Week Range
- $22.66 – $42.48
- Volume
- 1.57 million shs
- Average Volume
- 1.39 million shs
- Market Cap
- $3.09 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.90%
- Days to Cover
- 1.33
About Parabilis Medicines, Inc. Common Stock
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Related Stocks
Compare head-to-head: PBLS vs LLY·PBLS vs JNJ·PBLS vs ABBV·PBLS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.